NCT01460979

Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma

Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 47 (actual)
• Sponsor: AGO Study Group · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the activity, tolerability and safety of Temsirolimus in women with ovarian cancer who progressed during the previous platinum chemotherapy alternatively within 6 months from completion of therapy or advanced endometrial carcinoma.

Conditions

• Genital Diseases, Female
• Ovarian Diseases
• Ovarian Neoplasms
• Endometrial Neoplasms

Interventions

Type	Name	Description
DRUG	Temsirolimus	25mg weekly intravenous until progression

Timeline

• Start date: 2011-10-01
• Primary completion: 2015-06-01
• Completion: 2015-11-01
• First posted: 2011-10-27
• Last updated: 2016-02-29

Locations

18 sites across 1 country: Germany